
Ferrari starts year with racing profit but warns of tariff impact
Italian luxury carmaker Ferrari reported a robust first quarter with a 17% increase in its net profit to €412 million for the first three months of 2025, slightly better than expected. The carmaker also warned that US trade tariffs could hit earnings later this year.
Net revenues for Q1 2025 were €1.8bn, 13% more than in the previous year.
'Another year is off to a great start,' Benedetto Vigna, CEO of Ferrari, said. 'In the first quarter of 2025, with very few incremental shipments year on year, all key metrics recorded double-digit growth, underscoring a strong profitability driven by our product mix and continued demand for personalisations.'
Revenues from the car-making business were up by 11.1%, partially due to increased personalisations.
Overall shipments increased by 0.9% in the first quarter, mainly driven by demand in the EMEA region and the US, but shipments to Mainland China, Hong Kong and Taiwan decreased.
Revenues from sponsorship, commercial and brand were up by 32.1%.
Related
Ferrari raises prices for certain models in response to Trump's auto tariffs
Ferrari posts strong results as luxury personalisation demand rises
Outlook for 2025
For the full year 2025, the Italian carmaker expects net revenues to be up by 5% year-on-year, resulting in more than €7bn. According to its guidance, the adjusted operating profit is expected to be around or more than €2.03bn, up by 7% or more.
However, the carmaker warned that this profit could be reduced if US tariffs hit the carmaker harder than expected. 'The above guidance is subject to a potential risk of 50 basis points reduction on profitability percentage margins (EBIT and EBITDA margins), in relation to the update of the commercial policy following the introduction of import tariffs on EU cars into the USA,' the statement said.
At the end of March, Ferrari already announced that it would increase their prices for certain models up to 10% in response to Trump's 25% auto tariffs on European car imports.
'We continue to enrich our product offering – in line with our plans – with six new models this year, which include the newly launched 296 Speciale, 296 Speciale A and the much-anticipated Ferrari elettrica through a unique and innovative unveiling,' Vigna said. 'We are very excited about what lies ahead.'
Ferrari's share prices were more than 1.8% up after the report at 4.30 p.m. CEST in the Italian trade on Euronext Milan.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
LeMonde
2 hours ago
- LeMonde
Trump confirms extension of China tariff truce by 90 days
US President Donald Trump said Monday, August 11, he has ordered a 90-day tariff truce to delay reimposition of higher levies on Chinese goods, hours before a suspension between the two economies was set to expire. "I have just signed an Executive Order that will extend the Tariff Suspension on China for another 90 days. All other elements of the Agreement will remain the same," Trump posted on his Truth Social platform. While the United States and China slapped escalating tariffs on each other's products this year, bringing them to prohibitive triple-digit levels and snarling trade, both countries in May agreed to temporarily lower them. Their 90-day halt of steeper levies was due to expire Tuesday. Asked about the deadline earlier Monday, Trump said: "We'll see what happens. They've been dealing quite nicely. The relationship is very good with President Xi (Jinping) and myself." Trump also touted the tariff revenue his country has collected since his return to the White House, saying "we've been dealing very nicely with China." "We hope that the US will work with China to follow the important consensus reached during the phone call between the two heads of state," Chinese foreign ministry spokesman Lin Jian said in a statement. He added that Beijing also hopes Washington will "strive for positive outcomes on the basis of equality, respect and mutual benefit."


France 24
4 hours ago
- France 24
Trump meets with Intel CEO after demanding he resign
Trump said on his Truth Social platform that he met with Lip-Bu Tan along with Secretary of Commerce Howard Lutnick and Secretary of Treasury Scott Bessent. "The meeting was a very interesting one," Trump said in the post. "His success and rise is an amazing story." Trump added that members of his cabinet are going to spend time with Tan and bring the president "suggestions" next week. Intel did not respond to a request for comment. Trump demanded last week that the recently-hired boss of Intel resign "immediately," after a Republican senator raised national security concerns over his links to firms in China. "The CEO of INTEL is highly CONFLICTED and must resign, immediately. There is no other solution to this problem," Trump posted on Truth Social last Thursday. Tan released a statement at the time saying that the company was engaged with the Trump administration to address the concerns raised and ensure officials "have the facts." Intel is one of Silicon Valley's most iconic companies but its fortunes have been dwarfed by Asian powerhouses TSMC and Samsung, which dominate the made-to-order semiconductor business. In a statement, Tan said there has been "a lot of misinformation circulating" about his past roles at Walden International and Cadence Design Systems. "I have always operated within the highest legal and ethical standards," Tan said. The Malaysia-born tech industry veteran took the helm at struggling Intel in March, announcing layoffs as White House tariffs and export restrictions muddied the market. Intel's niche has been chips used in traditional computing processes, which are steadily being eclipsed by the AI revolution.

LeMonde
5 hours ago
- LeMonde
Trump keeps up the pressure on pharmaceutical companies amid tariff uncertainty
In recent months, pressure on pharmaceutical manufacturers has continued to mount across the Atlantic due to tariff uncertainty, demands for lower drug prices and disruptions caused by shifting policies or staff changes within US health agencies. Although laboratories remain exempt from tariffs for now, they have tried to present a relatively calm front. Still, Donald Trump's repeated attacks on the industry do little to ease concerns. The US president once again caused a stir on August 5. Speaking on CNBC, Trump reiterated his threat to raise tariffs on health products imported into the US to dramatic levels, aiming to force drug manufacturers to bring their production back onto American soil. "We'll be putting an initially small tariff on pharmaceuticals, but in one year, one-and-a-half years maximum, it's going to go to 150%, then it's going to go to 250%, because we want pharmaceuticals made in our country," he stated. Manufacturers − under pressure for months from the US administration to comply with Trump's demands − have already announced a series of major investments in the US since February. American laboratories such as Eli Lilly, Johnson & Johnson, AbbVie, Bristol Myers Squibb, Gilead and Regeneron; Swiss companies Roche and Novartis; Japan's Takeda; France's Sanofi; and the United Kingdom's AstraZeneca have together pledged nearly $320 billion over the next five years to strengthen and expand their industrial presence in the US.